Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
B cells and multiple sclerosis.
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Determination and characterization of a cannabinoid receptor in rat brain.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Alerting Network Dysfunction in Early Multiple Sclerosis.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

Pages